Pfizer Inc Stock Forecast for 2023 - 2025 - 2030
Updated on 04/01/2023
Pfizer Inc Stock Forecast and Price Target
The average target price for Pfizer Inc's stock set by eight renowned analysts in recent months is $52.65, representing a potential upside of approximately 29.08% from its last closing price if met by 2024. This estimation is based on a high estimate of $75.00 and a low estimate of $44.00. If you are looking to invest in the stock, it's important to research and compare different companies.
29.08% Upside
Pfizer Inc Fair Value Forecast for 2023 - 2025 - 2030
In the last three years, Pfizer Inc's Price has grown by 89.49%, from $36.70 to $69.54. 19 analysts predict Pfizer Inc's Fair Value will decrease by 2.33% in the next year, reaching $67.92. By 2030, professionals predict that Pfizer Inc's Fair Value will decrease by 42.04%, to $40.31.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
10
|
$154.95 | $181.05 | 16.49% |
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$343.42 | $333.19 | 16.48% |
| MRK Stock Forecast | Merck | Outperform |
5
|
$106.38 | $99.57 | 10.92% |
| BMY Stock Forecast | Bristol-Myers Squibb Co | Outperform |
2
|
$69.31 | $80.99 | 19.75% |
| REGN Stock Forecast | Regeneron Pharmaceuticals Inc | Outperform |
2
|
$821.67 | $796.73 | -4.83% |
Pfizer Inc Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Pfizer Inc's Revenue has grown by 145.28%, from $40.91B to $100.33B. 17 analysts predict Pfizer Inc's Revenue will decrease by 20.35% in the next year, reaching $79.92B. By 2030, professionals predict that Pfizer Inc's Revenue will decrease by 47.10%, to $53.07B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| VRTX Stock Forecast | Vertex Pharmaceuticals Inc | Outperform |
16
|
$315.03 | $323.74 | 3.48% |
| ZTS Stock Forecast | Zoetis | Outperform |
18
|
$166.42 | $209.70 | 23.18% |
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$40.56 | $60.73 | 43.00% |
Pfizer Inc Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, Pfizer Inc's Dividend per Share has grown from $1.44 to $1.64 – a 13.89% increase. Next year, analysts are expecting Dividend per Share to reach $1.68 – an increase of 2.44%. Over the next eight years, the forecast is for Dividend per Share to grow by 3.05%.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| ALNY Stock Forecast | Alnylam Pharmaceuticals Inc | Outperform |
7
|
$200.32 | $244.18 | 25.30% |
| VTRS Stock Forecast | Viatris | Outperform |
8
|
$9.62 | $13.70 | 40.33% |
| UTHR Stock Forecast | United Therapeutics | Outperform |
12
|
$223.94 | $280.69 | 31.73% |
Pfizer Inc Free Cash Flow Forecast for 2023 - 2025 - 2030
In the last three years, Pfizer Inc's Free Cash Flow has grown by 309684947.88%, rising from $10.54B to $32647.00T. The next year, 7 experts forecast that Pfizer Inc's Free Cash Flow will decrease by 100.00%, reaching $30.67B. In 2030, professionals predict that Pfizer Inc's Free Cash Flow will decrease by 100.00%, reaching $15.21B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| CTLT Stock Forecast | Catalent | Outperform |
15
|
$65.69 | $83.92 | 11.13% |
| IONS Stock Forecast | Ionis Pharmaceuticals | Hold |
9
|
$35.77 | $52.42 | 39.78% |
| CYTK Stock Forecast | Cytokinetics | Outperform |
10
|
$35.19 | $62.67 | 70.50% |
Pfizer Inc Net Income Forecast for 2023 - 2025 - 2030
In the last three years, Pfizer Inc's Net Income has grown by 95.98%, rising from $16.03B to $31.41B. For next year, analysts predict Net Income of $31.82B, which would mean an increase of 1.32%. According to professionals, by 2030, Pfizer Inc's Net Income will have decreased by 40.08%, falling down to $18.82B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| BCPC Stock Forecast | Balchem | Outperform |
18
|
$126.48 | $163.67 | 29.66% |
| NEOG Stock Forecast | Neogen | Hold |
16
|
$18.52 | $37.00 | 37.69% |
| CORT Stock Forecast | Corcept Therapeutics | Outperform |
16
|
$21.64 | $0.00 | 36.32% |
Pfizer Inc EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Pfizer Inc's EBITDA has grown, rising from $13.86B to $43.64B – a growth of 214.92%. According to the 10 analysts polled, in the next year, Pfizer Inc's EBITDA will fall by 14.50%, reaching $37.31B. By 2030, professionals believe that Pfizer Inc's EBITDA will have decreased by 55.44%, falling to $19.44B.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| TGTX Stock Forecast | TG Therapeutics | Outperform |
9
|
$15.05 | $73.38 | 26.25% |
| INDV Stock Forecast | Indivior PLC | Buy |
14
|
£171.80 | £3.79 | -97.24% |
| PCRX Stock Forecast | Pacira BioSciences | Outperform |
16
|
$40.79 | $79.67 | 91.22% |
Pfizer Inc EBIT Forecast for 2023 - 2025 - 2030
Pfizer Inc's EBIT has grown In the last two years, rising from $8.14B to $26.85B – a growth of 229.71%. In the next year, analysts believe that EBIT will reach $33.76B – an increase of 25.78%. By 2030, professionals believe that Pfizer Inc's EBIT will decrease by 19.82%, reaching $21.52B – a concerning trend for the company.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| AMPH Stock Forecast | Amphastar Pharmaceuticals | Outperform |
14
|
$37.48 | $41.00 | 17.40% |
| IRWD Stock Forecast | Ironwood Pharmaceuticals | Hold |
14
|
$10.53 | $12.60 | 18.71% |
| SUPN Stock Forecast | Supernus Pharmaceuticals | Outperform |
16
|
$36.28 | $35.50 | -6.28% |
Pfizer Inc EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last three years, Pfizer Inc's EPS has grown by 89.49%, from $2.95 to $5.59. 19 analysts predict Pfizer Inc's EPS will decrease by 2.33% in the next year, reaching $5.46. By 2030, professionals predict that Pfizer Inc's EPS will decrease by 42.04%, to $3.24.
| Ticker | Name | Consensus | Stock Rating | Price | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|
| LGND Stock Forecast | Ligand Pharmaceuticals | Outperform |
14
|
$73.56 | $195.43 | 115.47% |
| MDGL Stock Forecast | Madrigal Pharmaceuticals | Outperform |
4
|
$242.26 | $170.08 | -27.76% |
| USNA Stock Forecast | USANA Health Sciences | Hold |
14
|
$62.90 | $104.00 | -9.38% |